New Opportunities in Endometriosis Treatment
This carefully selected group of biopharmaceutical stocks represents companies that could benefit from Organon's recent discontinuation of its endometriosis drug. Our analysts have identified these firms as potential leaders in addressing the significant unmet needs in women's health.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Femasys Inc
FEMY
Current price
$0.72
As a biomedical company focused on addressing unmet needs in women's health, the failure of a major endometriosis candidate could draw significant att...
As a biomedical company focused on addressing unmet needs in women's health, the failure of a major endometriosis candidate could draw significant attention to its portfolio of solutions.
TherapeuticsMD, Inc.
TXMD
Current price
$0.90
This women's health company's approved products could see renewed focus as a competitor's pipeline drug for endometriosis fails, highlighting the valu...
This women's health company's approved products could see renewed focus as a competitor's pipeline drug for endometriosis fails, highlighting the value of existing treatments.
FibroGen Inc
FGEN
Current price
$0.29
FibroGen has investigated treatments for uterine fibroids, a related condition; with a major competitor out, its pipeline in the broader fibrotic dise...
FibroGen has investigated treatments for uterine fibroids, a related condition; with a major competitor out, its pipeline in the broader fibrotic disease space could gain traction.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
With Organon halting development of OG-6219, the endometriosis treatment landscape has dramatically shifted. Companies pursuing novel therapies for this condition now face less competition in a market with persistent, high unmet medical needs affecting millions of women worldwide.
What You Need to Know
This group includes companies across various stages of development, from early research to late-stage clinical trials. They span women's health, immunology, fibrotic diseases, and other therapeutic areas with technologies potentially applicable to endometriosis treatment.
Why These Stocks
These companies were selected because they have pipelines or technologies relevant to women's health or adjacent therapeutic areas. With a major competitor's exit, they're now better positioned to attract capital, form partnerships, and potentially capture market share in this specialized field.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+625.07%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 625.07% over the next year.
Stocks Rated Buy by Analysts
11 of 13 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 5.7% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
Breakthrough Potential
With Organon's exit, these companies now have clearer paths to becoming leaders in a multi-billion dollar market. Early investors could benefit from clinical success or acquisition interest.
Addressing a Widespread Need
Endometriosis affects roughly 1 in 10 women worldwide, yet treatment options remain limited. Companies that successfully develop effective therapies could capture significant market share in this underserved space.
Catalyst-Driven Opportunity
This is a timely investment theme triggered by a specific market event. The competitive landscape has suddenly shifted, potentially accelerating partnerships, funding, and clinical development for these companies.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.